| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701495 | Journal of Thoracic Oncology | 2017 | 24 Pages |
Abstract
The reduced toxicity and the documented low rate of marginal failures make the adaptive approach a modern option for future randomized studies. The best scenario to confirm its application is probably in neoadjuvant chemoradiation trials.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Sara MD, Michele MD, Sonia MD, Maria Cristina MD, Massimo MD, Antonio Maria MD, Paolo MD, Elisabetta MD, Patrizia Cornacchione, Carlo MD, Lucio MD, Edy MD, Rolando Maria MD,